PARP inhibitors (PARPi) including olaparib, niraparib, rucaparib, and talazoparib have been approved as monotherapy for patients with BRCA1/2-mutated ovarian cancers, breast cancer, pancreatic cancer, and prostate cancer2,3. This evidence concerns the gene BRCA1 and ovarian carcinoma.